Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis - Results of a longitudinal magnetic resonance spectroscopy study

被引:411
作者
De Stefano, N
Matthews, PM
Fu, LQ
Narayanan, S
Stanley, J
Francis, GS
Antel, JP
Arnold, DL
机构
[1] Montreal Neurol Hosp & Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada
[2] Univ Siena, Neurometab Unit, Inst Neurol Sci, I-53100 Siena, Italy
[3] Univ Oxford, Radcliffe Infirm, Dept Clin Neurol, Oxford OX2 6HE, England
关键词
multiple sclerosis; axons; disability; magnetic resonance spectroscopy; N-acetylaspartate;
D O I
10.1093/brain/121.8.1469
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
It has been difficult to establish a strong correlation between total brain T-2-weighted lesion volume on MRI and clinical disability in multiple sclerosis, in part because of the lack of pathological specificity of T-2-weighted MRI signal changes. Proton magnetic resonance spectroscopy studies have shown that measurements of the resonance intensity of N-acetylaspartate (which is localized exclusively in neurons and neuronal processes in the mature brain) can provide a specific index of axonal damage or dysfunction. Here we report a 30-month longitudinal study of 29 patients with multiple sclerosis who had either a relapsing or a secondary progressive clinical course, Conventional brain MRI and single-voxel proton magnetic resonance spectroscopy examinations were obtained at intervals of 6-8 months with concurrent clinical evaluation. At the onset of the study, the brain N-acetylaspartate : creatine resonance intensity ratio was abnormally low for the whole group of patients (control mean = 2.93 +/- 0.2, patient mean = 2.56 +/- 0.4, P < 0.005). There were no significant differences between the relapsing and secondary progressive subgroups. Over the follow-up period, there was a trend towards a decrease (8%) in the brain N-acetylaspartate: creatine ratio for the 11 relapsing patients and a significant (P < 0.001) correlation between changes in the brain N-acetyl-aspartate : creatine ratio and expanded disability scale scores for the patients in this group. This correlation was even more evident for the patients who had clinically relevant relapses during the 30 months of follow-up (seven of 11 patients). Increases in T-2-weighted lesion volumes (35% in 30 months for the group as a whole, P < 0.0001, without differences between the subgroups) did not correlate with disability either in the group of patients as a whole or in the different subgroups. We conclude that indices of axonal damage or loss such as brain N-acetylaspartate may provide a specific measure of pathological changes relevant to disability. Total T-2-weighted lesion volumes, although more sensitive to changes with time than brain N-acetylaspartate, may be less relevant to understanding the progression of disability.
引用
收藏
页码:1469 / 1477
页数:9
相关论文
共 55 条
  • [31] PROTON MAGNETIC-RESONANCE SPECTROSCOPY FOR METABOLIC CHARACTERIZATION OF PLAQUES IN MULTIPLE-SCLEROSIS
    MATTHEWS, PM
    FRANCIS, G
    ANTEL, J
    ARNOLD, DL
    [J]. NEUROLOGY, 1991, 41 (08) : 1251 - 1256
  • [32] Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy
    Matthews, PM
    Pioro, E
    Narayanan, S
    DeStefano, N
    Fu, L
    Francis, G
    Antel, J
    Wolfson, C
    Arnold, DL
    [J]. BRAIN, 1996, 119 : 715 - 722
  • [33] RACHELLE-FISHMAN-MATTHEW-MOORE-LECTURE - THE PATHOLOGICAL AND CLINICAL DYNAMICS OF MULTIPLE-SCLEROSIS
    MCDONALD, WI
    [J]. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1994, 53 (04) : 338 - 343
  • [34] MAGNETIC-RESONANCE IN MONITORING THE TREATMENT OF MULTIPLE-SCLEROSIS
    MILLER, DH
    [J]. ANNALS OF NEUROLOGY, 1994, 36 : S91 - S94
  • [35] PROTON MAGNETIC-RESONANCE SPECTROSCOPY OF AN ACUTE AND CHRONIC LESION IN MULTIPLE-SCLEROSIS
    MILLER, DH
    AUSTIN, SJ
    CONNELLY, A
    YOUL, BD
    GADIAN, DG
    MCDONALD, WI
    [J]. LANCET, 1991, 337 (8732) : 58 - 59
  • [36] Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis
    Miller, DH
    Albert, PS
    Barkhof, F
    Francis, G
    Frank, JA
    Hodgkinson, S
    Lublin, FD
    Paty, DW
    Reingold, SC
    Simon, J
    [J]. ANNALS OF NEUROLOGY, 1996, 39 (01) : 6 - 16
  • [37] MAGNETIC-RESONANCE-IMAGING AND SPECTROSCOPY IN MULTIPLE-SCLEROSIS
    MILLER, DH
    [J]. CURRENT OPINION IN NEUROLOGY, 1995, 8 (03) : 210 - 215
  • [38] IMMUNOHISTOCHEMICAL LOCALIZATION OF N-ACETYLASPARTATE IN RAT-BRAIN
    MOFFETT, JR
    NAMBOODIRI, MAA
    CANGRO, CB
    NEALE, JH
    [J]. NEUROREPORT, 1991, 2 (03) : 131 - 134
  • [39] ORDIDGE RJ, 1987, ANN NY ACAD SCI, V508, P376
  • [40] Evaluation of multiple sclerosis by H-1 spectroscopic imaging at 4.1 T
    Pan, JW
    Hetherington, HP
    Vaughan, JT
    Mitchell, G
    Pohost, GM
    Whitaker, JN
    [J]. MAGNETIC RESONANCE IN MEDICINE, 1996, 36 (01) : 72 - 77